This team has very successful track records in medical device markets and in developing significant technology to enhance clinical results for millions of patients.
PORTLAND, Ore. (PRWEB) October 25, 2022
YorLabs, a developer of cutting-edge intracardiac image guided therapy solutions, today announced the appointment of Gregory “Greg” D. Casciaro to the company’s Board of Directors. Casciaro has 40 years of medical device experience and has held leadership roles in both public and private companies.
“We are pleased to welcome Greg to the YorLabs leadership team,” said Glen McLaughlin, president and CEO, YorLabs. “His extensive experience in the medical device industry, including several cardiac therapy solutions companies, will provide superb insights and guidance in our goal of developing the next generation, intracardiac image guided therapy platform.”
Casciaro is currently the president and CEO of Foldax Inc, the maker of Tria Heart Valves. Previously, he was the CEO, president and director of Cardiac Dimensions, as well as AccessClosure, Inc., a medical device company that was acquired by Cardinal Health. He also served in similar capacities at XTENT, a medical device company acquired by Biosensors International Group, and Orquest, a private company manufacturing and selling biotherapeutic products to the orthopedic market, which was acquired by DePuy Acromed, a division of Johnson and Johnson. He has been a member of the board of directors of QT Vascular Ltd., a Singaporean-listed company engaged in the design, assembly and distribution of therapeutic solutions for the minimally invasive treatment of complex vascular diseases, since 2001. Casciaro graduated from Marquette University with a B.S. in Business Administration.
“I joined the Yorlabs board, because of the high quality team Glen has assembled,” said Casciaro. “This team has very successful track records in medical device markets and in developing significant technology to enhance clinical results for millions of patients. It is exciting to join YorLabs in its endeavors to enable excellence in patient care.”
Today’s cath lab faces numerous challenges including capital constraints and disparate systems within the interventional cardiac (IC) and Electrophysiology (EP) markets. YorLabs’ vision is to provide a comprehensive, integrated therapy imaging solution with outstanding image quality and significantly improved workflow, while offering relief from large capital outlays and enabling ongoing, state-of-the art visualization.
To this end, YorLabs is designing its solution to provide automatic upgrades to maintain cutting-edge technology throughout the lifecycle of the platform. The company is developing novel algorithms to enable world class, intracardiac image guided therapy performance with dedicated application and procedural based settings and offerings. This solution will be an intuitive user interface platform, resulting in significant clutter and size reduction along with a greatly enhanced workflow.
“Greg is well qualified to serve on our board of directors,” said Anshumali Roy, founder and chief technology officer for YorLabs. “He has extensive management experience with growth companies and in mergers and acquisitions in the medical device industry – all of which will benefit YorLabs in successfully achieving its vision.”
Today’s Cath Lab faces numerous challenges including capital constraints and disparate systems. YorLabs is developing a world class, intracardiac image guided therapy platform with dedicated application and procedural based settings. The YorLabs solution is designed to be an intuitive platform while eliminating large capital outlays and significantly enhancing workflow. For further information, visit http://www.yorlabs.com.